The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance
The biopsy based 17-gene GPS was clinically validated to predict the likelihood of adverse surgical pathology in men with NCCN® very low, low or low-intermediate risk prostate cancer. We performed a prospective study to assess the impact of incorporating GPS into treatment recommendations in 3 high volume urology practices.
Men with newly diagnosed prostate cancer meeting specific NCCN criteria were prospectively enrolled in the trial. Biopsy tissue was analyzed. Urologists indicated treatment recommendations on questionnaires administered before and after GPS. The primary study objectives were to assess all changes in treatment modality and/or treatment intensity after GPS.
A total of 158 men were included in analysis, including 35, 71 and 52 at NCCN very low, low and low-intermediate risk. Biological risk predicted by GPS differed from NCCN clinical risk alone in 61 men (39%). Overall 18% of recommendations between active surveillance and immediate treatment changed after GPS. The relative increase in recommendations for active surveillance was 24% (absolute change 41% to 51%). In 41 of 158 men (26%) modality and/or intensity recommendations changed after GPS, including 25, 14 and 2 in whom recommendation intensity decreased, increased and were equivocal, respectively. All changes were directionally consistent with GPS. The NCCN low risk group showed the greatest absolute recommendation change after GPS (37%). In 17 of 57 men (30%) the initial recommendation of radical prostatectomy was changed to active surveillance after GPS. Urologists indicated greater confidence and found that incorporating GPS was useful in 85% and 79% of cases, respectively, including when biological risk confirmed the clinical risk category.
This study demonstrates that the 17-gene GPS influenced treatment recommendations among urologists and provided increased confidence in these recommendations in patients at NCCN very low to low-intermediate risk.
- 1 : Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol2010; 28: 1117. Google Scholar
- 2 : Critical review of prostate cancer predictive tools. Future Oncol2009; 5: 1555. Google Scholar
- 3 : Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol2006; 176: 979. Link, Google Scholar
- 4 : The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol2009; 181: 95. Link, Google Scholar
- 5 : Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol2011; 186: 1286. Link, Google Scholar
- 6 : A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol2014; 66: 550. Google Scholar
- 7 : Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics2013; 14: 690. Google Scholar
- 8 NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, version 2.2014. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed August 21, 2014. Google Scholar
- 9 : The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol2013; 24: 618. Google Scholar
- 10 : The influence of a gene expression profile on breast cancer decisions. J Surg Oncol2009; 99: 319. Google Scholar
- 11 : The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist2011; 16: 1520. Google Scholar
- 12 : Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health2010; 13: 381. Google Scholar
- 13 : Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist2010; 15: 457. Google Scholar
- 14 : Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. Value Health2013; 16: 729. Google Scholar
- 15 : Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat2011; 127: 739. Google Scholar
- 16 : Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat2012; 133: 1115. Google Scholar
- 17 : Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manag Care2011; 17: 455. Google Scholar
- 18 : Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care2005; 11: 313. Google Scholar
- 19 : Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med2014; 174: 1450. Google Scholar
- 20 : Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int2014; 114: 320. Google Scholar